CoChat

Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D

Zhou, Chuan, Fan, Zisheng, Gu, Yuejiao, Ge, Zhiming, Tao, Zhaofan, Cui, Rongrong, Li, Yupeng, Zhou, Guizhen, Huo, Ruifeng, Gao, Mingshan, Wang, Dan, He, Wei, Zheng, Mingyue, Zhang, Sulin, Xu, Tianfeng · 2024 · Journal of Medicinal Chemistry

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

KRAS G12D, the most frequent KRAS oncogenic mutation, is a promising target for cancer therapy. Herein, we report the design, synthesis, and biological evaluation of a series of KRAS G12D PROTACs by connecting the analogues of MRTX1133 and the VHL ligand. Structural modifications of the linker moiety and KRAS inhibitor part suggested a critical role of membrane permeability in the degradation activity of the KRAS G12D PROTACs. Mechanism studies with the representative compound 8o demonstrated that the potent, rapid, and selective degradation of KRAS G12D induced by 8o was via a VHL- and proteasome-dependent manner. This compound selectively and potently suppressed the growth of multiple KRAS G12D mutant cancer cells, displayed favorable pharmacokinetic and pharmacodynamic properties in mice, and showed significant antitumor efficacy in the AsPC-1 xenograft mouse model. Further optimization of 8o appears to be promising for the development of a new chemotherapy for KRAS G12D -driven cancers as the complementary therapeutic strategy to KRAS inhibition.

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.3c01622

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Cited by

See all 46

Metadata

Authors
Zhou, C., Fan, Z., Gu, Y., Ge, Z., Tao, Z., Cui, R., Li, Y., Zhou, G., Huo, R., Gao, M., Wang, D., He, W., Zheng, M., Zhang, S., & Xu, T.
Affiliations
  • Chinese Academy of Sciences (CN)
  • The University of Texas at El Paso (US)
  • Nanjing University of Chinese Medicine (CN)
  • Nanchang University (CN)
Corresponding author
  • Zheng, Mingyue
  • Zhang, Sulin
  • Xu, Tianfeng
Venue
Journal of Medicinal Chemistry
Published
2024-01-10
Volume
67
Issue
2
Pages
1147-1167
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W4390705036
Cited by
45
References
48
Citations by year
2026: 14 · 2025: 19 · 2024: 12
FWCI
6.11
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Youth Innovation Promotion Association of the Chinese Academy of Sciences (2023296)
  • National Natural Science Foundation of China (22107110, T2225002)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
Keywords
PROTAC degraders, KRAS G12D, oncogenic KRAS, MRTX1133, linker optimization, membrane permeability, proteasomal degradation, KRAS inhibitors, antitumor efficacy, KRAS-driven cancers
MeSH terms
Animals, Disease Models, Animal, Heterocyclic Compounds, 2-Ring, Humans, Mutation, Naphthalenes, Proto-Oncogene Proteins p21(ras), Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D. https://app.cochat.ai/papers/10.1021/acs.jmedchem.3c01622
The paper
Zhou, C., Fan, Z., Gu, Y., Ge, Z., Tao, Z., Cui, R., Li, Y., Zhou, G., Huo, R., Gao, M., Wang, D., He, W., Zheng, M., Zhang, S., & Xu, T. (2024). Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01622

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.